U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

The US Food and Drug Administration FDA has approved Empliciti elotuzumab injection for intravenous use in combination with pomalidomide and dexamethasone EPd for the treatment of adult patients with multiple myeloma who have received at least two prior t [...]

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

The addition of Darzalex daratumumab to the standard treatment combination consisting of Velcade bortezomib melphalan and prednisone VMP reduces disease progression or death by 50 among patients with newly diagnosed multiple myeloma who are not eligible t [...]